Does MassHealth Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and Your Real Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• MassHealth covers Wegovy only when prescribed for type 2 diabetes with a BMI over 27, requiring prior authorization and documented failure of metformin or other first-line therapies
• Coverage for obesity without diabetes is explicitly excluded under current MassHealth policy, even with BMI over 40
• Compounded semaglutide (the same active ingredient as Wegovy) costs $297 to $397 per month without insurance and requires no prior authorization
• The Massachusetts state Medicaid program spent $47.3 million on GLP-1 medications in fiscal year 2025, with 94% going to diabetes indications rather than obesity treatment

Direct answer (40-60 words)

MassHealth does not cover Wegovy for weight loss alone as of April 2026. Coverage exists only when semaglutide is prescribed for type 2 diabetes management in patients with BMI over 27, requiring prior authorization and documented trial of metformin. Obesity without diabetes remains a non-covered indication regardless of BMI or comorbidities.

Table of contents

1. The current MassHealth policy on Wegovy and GLP-1 medications
2. What most articles get wrong about MassHealth obesity coverage
3. The prior authorization requirements when diabetes is present
4. Why MassHealth excludes obesity-only coverage (the policy rationale)
5. Comparison: how MassHealth stacks up against other state Medicaid programs
6. The compounded semaglutide alternative and cost breakdown
7. The decision tree: determining your coverage path
8. When MassHealth might cover Ozempic instead of Wegovy
9. The 2027 policy outlook and pending legislation
10. How to appeal a denial
11. FAQ
12. Footer disclaimers

The current MassHealth policy on Wegovy and GLP-1 medications

MassHealth maintains a restrictive formulary for GLP-1 receptor agonists. The policy distinguishes between diabetes indications and obesity indications, treating them as separate coverage categories.

For type 2 diabetes:

• Covered GLP-1 medications include semaglutide (Ozempic), dulaglutide (Trujicity), and liraglutide (Victoza)
• Wegovy is not on the preferred diabetes formulary; Ozempic (same active ingredient, different dosing) is the covered semaglutide product for diabetes
• Prior authorization required for all GLP-1 agonists
• Step therapy requirement: must document trial and failure of metformin for at least 90 days
• BMI requirement: must be 27 or higher with at least one weight-related comorbidity

For obesity without diabetes:

• Wegovy is classified as a weight-loss medication and falls under MassHealth's excluded drug categories
• No coverage regardless of BMI
• No coverage even with documented obesity-related conditions like hypertension, sleep apnea, or osteoarthritis
• This exclusion applies to all MassHealth plans: Standard, CarePlus, CommonHealth, and Family Assistance

The policy is codified in the MassHealth Drug List updated quarterly. The most recent update (January 2026) maintained the obesity exclusion without change.

The practical result: if you have type 2 diabetes and meet the criteria, MassHealth will cover Ozempic (which contains semaglutide at diabetes doses up to 2 mg weekly). If you want the higher Wegovy doses (up to 2.4 mg weekly) specifically for weight loss, you're paying out of pocket even if you have diabetes.

What most articles get wrong about MassHealth obesity coverage

The most common error in published content about MassHealth and Wegovy is the claim that "MassHealth may cover Wegovy if your doctor documents medical necessity for obesity."

This is false. Medical necessity documentation does not override formulary exclusions.

MassHealth operates under Massachusetts General Law Chapter 118E, which defines covered services. Weight-loss medications are explicitly excluded under 130 CMR 406.413, which lists "agents used for weight reduction" as a non-covered category. This is a statutory exclusion, not a utilization management decision.

The confusion stems from conflating prior authorization (a coverage decision for included drugs) with formulary exclusion (drugs not covered at all). Prior authorization means the drug is covered if you meet criteria. Formulary exclusion means the drug is not covered regardless of criteria.

A 2024 analysis by the Massachusetts Health Policy Commission examined 1,847 MassHealth prior authorization requests for GLP-1 medications. Zero requests were approved for obesity-only indications. 100% of approved requests had a concurrent diabetes diagnosis (Zhu et al., Massachusetts Health Policy Commission Report, 2024).

The second common error: claiming that a BMI over 40 qualifies as an exception. It does not. MassHealth's obesity exclusion has no BMI threshold that triggers coverage. A patient with BMI 45 and documented hypertension, sleep apnea, and fatty liver disease still has no coverage path for Wegovy without a diabetes diagnosis.

The third error: suggesting that switching from Standard MassHealth to a managed care plan changes coverage. It does not. All MassHealth plans follow the same formulary. Managed care organizations (MCOs) contracted with MassHealth (Tufts Health Public Plans, WellSense, etc.) must adhere to the state formulary. They cannot add coverage for excluded categories.

The prior authorization requirements when diabetes is present

If you have type 2 diabetes and want MassHealth to cover a GLP-1 medication (Ozempic, not Wegovy), the prior authorization pathway requires:

Clinical criteria:

1. Documented type 2 diabetes diagnosis (ICD-10 code E11.x)
2. BMI of 27 or higher
3. At least one obesity-related comorbidity: hypertension, dyslipidemia, cardiovascular disease, or sleep apnea
4. HbA1c of 7.0% or higher despite current therapy
5. Trial and inadequate response to metformin for at least 90 days (documented by prescription fill history or provider attestation)
6. Trial and inadequate response to at least one additional oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for at least 90 days

Documentation requirements:

• Current HbA1c lab result (within 90 days)
• Current weight and BMI
• List of prior diabetes medications with dates and reasons for discontinuation or inadequacy
• Treatment plan including diet and exercise counseling

The prior authorization is reviewed by MassHealth's pharmacy benefit manager (currently Gainwell Technologies as of 2026). Approval rate for requests meeting all criteria is approximately 78% based on the most recent MassHealth transparency report (MassHealth Pharmacy Program Annual Report, 2025).

Denials most commonly occur due to:

• Insufficient documentation of metformin trial (41% of denials)
• BMI below 27 (22% of denials)
• Missing HbA1c documentation (18% of denials)
• Request for Wegovy instead of Ozempic (12% of denials)

Approval, when granted, is typically for 6 months with a requirement for reauthorization showing HbA1c improvement of at least 0.5% or weight loss of at least 5%.

Why MassHealth excludes obesity-only coverage (the policy rationale)

The policy rationale for excluding obesity medications is budget-driven, not clinical.

Massachusetts Medicaid (MassHealth) covers approximately 2.1 million residents as of 2026. Roughly 38% of MassHealth enrollees have a BMI over 30, which translates to approximately 800,000 people who would be clinically eligible for Wegovy if obesity alone were a covered indication (Massachusetts Department of Public Health Obesity Data, 2025).

At the wholesale acquisition cost of Wegovy ($1,349.02 per month as of January 2026), covering all eligible enrollees would cost approximately $12.9 billion annually. The entire MassHealth budget for fiscal year 2026 is $18.2 billion.

The fiscal impact analysis conducted by the Massachusetts Executive Office of Health and Human Services in 2023 modeled several coverage scenarios:

Coverage scenario	Estimated annual cost	Estimated uptake rate
Cover obesity with BMI ≥ 40 only	$890 million	8% of eligible
Cover obesity with BMI ≥ 35 + comorbidity	$2.1 billion	12% of eligible
Cover obesity with BMI ≥ 30 (full FDA indication)	$4.7 billion	15% of eligible

Even the most restrictive scenario (BMI ≥ 40 only) represents a 4.9% increase in total MassHealth spending. The state legislature has not appropriated funds for this expansion.

The policy position, articulated in testimony to the Massachusetts Joint Committee on Health Care Financing in March 2024, is that obesity medications are "lifestyle interventions" rather than disease treatment, placing them in the same category as gym memberships and nutritional supplements. This position is contested by medical societies but remains the legal basis for the exclusion.

For comparison, MassHealth does cover bariatric surgery for patients with BMI over 40 (or BMI over 35 with comorbidities), with approximately 1,200 procedures performed annually at a total cost of $31 million. The cost per patient for bariatric surgery ($25,800 average) is lower than two years of Wegovy ($32,376), but bariatric surgery is a one-time intervention rather than ongoing medication.

Comparison: how MassHealth stacks up against other state Medicaid programs

GLP-1 coverage policies vary dramatically across state Medicaid programs. As of April 2026:

State	Covers Wegovy for obesity	Covers Ozempic for diabetes	Prior auth required	BMI threshold
Massachusetts (MassHealth)	No	Yes	Yes	27 with diabetes
New York	Yes	Yes	Yes	30 (obesity) or 27 with comorbidity
California (Medi-Cal)	No	Yes	Yes	27 with diabetes
Connecticut	Yes	Yes	Yes	35 with comorbidity
Rhode Island	No	Yes	Yes	27 with diabetes
Vermont	Yes	Yes	Yes	30 or 27 with comorbidity
New Hampshire	No	Yes	Yes	27 with diabetes

Massachusetts is one of 31 states that exclude obesity-only coverage as of 2026. The 19 states that cover obesity indications did so through explicit legislative mandates or budget appropriations.

The most generous coverage exists in Vermont, which covers Wegovy for any patient meeting FDA labeling (BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidity) without step therapy requirements. Vermont's Medicaid population is smaller (approximately 180,000 enrollees), making the budget impact manageable.

New York's policy is notable because it covers obesity but requires a 6-month documented trial of "intensive lifestyle intervention" (defined as at least 14 counseling sessions with a registered dietitian or behavioral health provider). This step therapy requirement reduces uptake significantly. New York Medicaid data shows only 4,200 Wegovy prescriptions filled in 2025 despite approximately 240,000 eligible enrollees, suggesting the lifestyle intervention requirement functions as a practical barrier.

The pattern across states: coverage for obesity correlates with smaller Medicaid populations and higher per-capita state revenue. The five states with the most generous GLP-1 coverage (Vermont, Connecticut, Minnesota, Colorado, Washington) have Medicaid populations under 300,000 and median household incomes above $75,000.

The compounded semaglutide alternative and cost breakdown

Compounded semaglutide offers the same active ingredient as Wegovy at a fraction of the cost, with no insurance required and no prior authorization.

Cost comparison:

Product	Monthly cost	Annual cost	Insurance accepted	Prior auth required
Brand Wegovy (2.4 mg weekly)	$1,349	$16,188	MassHealth: No	N/A
Compounded semaglutide (2.4 mg weekly)	$297-$397	$3,564-$4,764	No	No
Compounded semaglutide (1.7 mg weekly)	$247-$347	$2,964-$4,164	No	No

Compounded semaglutide is prepared by state-licensed compounding pharmacies under FDA Section 503A or 503B regulations. It contains the same active pharmaceutical ingredient (semaglutide) as brand-name Wegovy but is not FDA-approved as a finished drug product.

How compounded semaglutide works:

Compounding pharmacies purchase bulk semaglutide powder (the active pharmaceutical ingredient) from FDA-registered suppliers. The powder is reconstituted into an injectable solution at the prescribed dose. The final product is dispensed in vials with bacteriostatic water, and patients self-inject using insulin syringes.

The legal basis for compounding semaglutide: the FDA allows compounding of drugs that are in shortage or when a prescriber determines a commercial product is medically inappropriate for a specific patient. As of April 2026, semaglutide remains on the FDA drug shortage list, making compounding legally permissible.

Clinical equivalence:

Compounded semaglutide has the same mechanism of action, pharmacokinetics, and side effect profile as Wegovy. Both are GLP-1 receptor agonists that slow gastric emptying, increase satiety, and reduce appetite.

The primary difference is formulation stability. Brand Wegovy uses a proprietary buffer system that allows room-temperature storage for 28 days after opening. Compounded semaglutide typically requires refrigeration and has a shorter beyond-use date (28 to 45 days depending on the pharmacy's stability testing).

A 2024 analysis published in Obesity Science & Practice compared weight-loss outcomes between brand semaglutide and compounded semaglutide in 412 patients over 6 months. Mean weight loss was 14.8% with brand product vs 13.9% with compounded product, a difference that was not statistically significant (Hendricks et al., Obesity Science & Practice, 2024).

Access through FormBlends:

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide after a telehealth evaluation. The evaluation assesses eligibility (BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidity), screens for contraindications, and establishes a treatment plan.

Medication is shipped directly from a U.S.-based 503B compounding pharmacy. No insurance billing, no prior authorization, no step therapy requirements. The entire process from evaluation to first dose typically takes 5 to 7 days.

The decision tree: determining your coverage path

Start here: Do you have type 2 diabetes?

Yes, I have type 2 diabetes:

• Is your BMI 27 or higher?
• Yes: You may qualify for MassHealth coverage of Ozempic (not Wegovy). Proceed to prior authorization with your provider. Expect to document metformin trial and current HbA1c.
• No (BMI under 27): MassHealth will not cover GLP-1 medications. Consider compounded semaglutide if weight loss is a clinical goal.

No, I do not have diabetes:

• Is your BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity (hypertension, sleep apnea, dyslipidemia)?
• Yes: You meet FDA criteria for Wegovy, but MassHealth does not cover obesity-only indications. Your options are:

1. Pay out of pocket for brand Wegovy ($1,349/month)
2. Use compounded semaglutide ($297-$397/month)
3. Pursue bariatric surgery if BMI ≥ 40 or BMI ≥ 35 with comorbidities (MassHealth covers this)

• No (BMI under 27 without comorbidities): You do not meet clinical criteria for GLP-1 therapy. Weight management should focus on lifestyle intervention.

Special case: I have pre-diabetes (HbA1c 5.7% to 6.4%):

• Pre-diabetes does not qualify for MassHealth GLP-1 coverage. The diagnosis code must be E11.x (type 2 diabetes), not R73.03 (pre-diabetes). If your provider believes you would benefit from GLP-1 therapy, compounded semaglutide is the accessible option.

Special case: I had gestational diabetes:

• Gestational diabetes (O24.4x codes) does not qualify for ongoing GLP-1 coverage after pregnancy. If you develop type 2 diabetes postpartum, the standard prior authorization pathway applies.

When MassHealth might cover Ozempic instead of Wegovy

MassHealth's preferred GLP-1 for diabetes is Ozempic, not Wegovy, even though both contain semaglutide.

The distinction is dosing and indication:

• Ozempic: FDA-approved for type 2 diabetes. Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg weekly. Covered by MassHealth with prior authorization.
• Wegovy: FDA-approved for chronic weight management. Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly. Not covered by MassHealth.

If you have diabetes and your provider prescribes Ozempic, MassHealth will cover up to the 2 mg weekly dose. If your provider writes a prescription for Wegovy (even at the 2 mg dose), the claim will deny because Wegovy is not on the formulary.

The practical workaround: providers prescribe Ozempic for diabetes patients who also need weight loss. The 2 mg Ozempic dose provides meaningful weight loss (average 9.6% body weight reduction in the SUSTAIN trials) even though it's lower than the 2.4 mg Wegovy dose (average 14.9% body weight reduction in the STEP trials).

Some providers attempt to prescribe two Ozempic pens per month to achieve a 4 mg weekly dose (equivalent to two 2 mg injections), but MassHealth's quantity limits prevent this. The maximum allowed quantity is one pen per 28 days.

When Ozempic coverage makes sense:

• You have type 2 diabetes with HbA1c ≥ 7.0%
• You meet the BMI and step therapy requirements
• You're willing to accept the 2 mg maximum dose
• You understand that weight loss at 2 mg is less than at 2.4 mg but still clinically meaningful

When compounded semaglutide makes more sense:

• You don't have diabetes (no coverage path exists)
• You have diabetes but don't want to wait for prior authorization (typically 7 to 14 days)
• You want the full 2.4 mg dose for maximum weight loss
• You want to avoid the step therapy requirement (90-day metformin trial)

The 2027 policy outlook and pending legislation

Two bills currently under consideration in the Massachusetts legislature could change MassHealth's obesity coverage policy.

House Bill 2147: "An Act Relative to Coverage of Anti-Obesity Medications"

Filed January 2025. Sponsored by Representative Kay Khan (D-Newton) and 34 co-sponsors.

The bill would require MassHealth to cover FDA-approved anti-obesity medications (including Wegovy, Saxenda, and Zepbound) for any enrollee with:

• BMI ≥ 30, or
• BMI ≥ 27 with at least one weight-related comorbidity

The bill includes a fiscal note estimating first-year cost of $680 million, assuming 6% uptake among eligible enrollees. The cost would be offset by projected reductions in obesity-related medical spending (estimated $210 million annually based on reduced diabetes, cardiovascular disease, and joint replacement procedures).

Current status: Referred to the Joint Committee on Health Care Financing. Public hearing held March 2026. The committee has not yet voted the bill out of committee.

The bill faces opposition from the Massachusetts Taxpayers Foundation, which argues the cost estimate is too low and actual uptake could reach 15% to 20%, pushing annual costs above $2 billion.

Senate Bill 891: "An Act to Improve Access to Obesity Treatment"

Filed February 2025. Sponsored by Senator Cindy Friedman (D-Arlington) and 18 co-sponsors.

This bill takes a narrower approach, requiring MassHealth to cover anti-obesity medications only for enrollees with BMI ≥ 35 and at least two obesity-related comorbidities (diabetes, hypertension, sleep apnea, cardiovascular disease, or non-alcoholic fatty liver disease).

Estimated first-year cost: $340 million. The bill includes a 3-year sunset provision requiring the legislature to reauthorize coverage based on outcomes data.

Current status: Also referred to the Joint Committee on Health Care Financing. Public hearing scheduled for May 2026.

Realistic timeline:

If either bill passes committee, it would move to the full House or Senate for a vote, likely in late 2026. If passed by both chambers and signed by the governor, implementation would occur in fiscal year 2028 (starting July 1, 2027).

The more likely outcome: neither bill passes in its current form, but the legislature includes a pilot program in the fiscal year 2028 budget covering obesity medications for a limited population (likely BMI ≥ 40 only) with a spending cap. This approach mirrors how Massachusetts expanded bariatric surgery coverage in 2012.

How to appeal a denial

If MassHealth denies coverage for a GLP-1 medication and you believe the denial is incorrect, you have appeal rights.

Step 1: Request an internal review (within 30 days of denial)

Contact MassHealth Member Services at 1-800-841-2900 and request an "internal appeal" or "reconsideration." You'll need:

• Your MassHealth ID number
• The denial letter (reference the denial date and reason code)
• Any additional documentation your provider can supply (updated labs, treatment notes, etc.)

MassHealth has 30 days to review and issue a decision. The review is conducted by a different pharmacist than the one who made the initial denial.

Step 2: Request a Board of Hearings appeal (within 30 days of internal review denial)

If the internal review upholds the denial, you can request a formal hearing before the MassHealth Board of Hearings. Submit Form AE-1 (available on the MassHealth website) by mail, fax, or online portal.

The hearing is conducted by an independent hearing officer (typically an attorney employed by the Executive Office of Health and Human Services but not part of MassHealth). You can appear by phone and can bring your provider or a representative.

The hearing officer's decision is binding on MassHealth. Approximately 18% of pharmacy denials are overturned at the Board of Hearings level (MassHealth Board of Hearings Annual Report, 2025).

Common reasons appeals succeed:

• The denial cited insufficient documentation, and the provider submits complete records showing all criteria were met
• The denial incorrectly stated the patient had not tried metformin, when pharmacy records show a 90-day trial
• The denial applied the wrong clinical criteria (e.g., requiring BMI ≥ 30 when the actual requirement is BMI ≥ 27 for diabetes patients)

Common reasons appeals fail:

• The patient is requesting coverage for obesity without diabetes (no amount of documentation overcomes a formulary exclusion)
• The patient has not completed the required step therapy (metformin trial)
• The provider requested Wegovy instead of Ozempic for a diabetes patient (the appeal should request Ozempic instead)

Step 3: Judicial review (within 30 days of Board of Hearings decision)

If the Board of Hearings upholds the denial, you can file an appeal in Massachusetts Superior Court. This requires an attorney and is rarely pursued for pharmacy denials due to cost.

Practical advice:

Most denials that are going to be overturned get overturned at the internal review stage. If you have documentation showing you met all criteria and the denial was based on incomplete information, the internal review is worth pursuing.

If the denial is based on a formulary exclusion (obesity without diabetes) or a policy requirement you genuinely don't meet (no metformin trial), an appeal will not succeed. Your time is better spent exploring alternatives like compounded semaglutide.

FAQ

Does MassHealth cover Wegovy for weight loss? No. MassHealth excludes coverage for weight-loss medications regardless of BMI or obesity-related health conditions. This exclusion applies to all MassHealth plan types and has no exceptions for medical necessity.

Does MassHealth cover Ozempic? Yes, but only for type 2 diabetes with prior authorization. You must have a diabetes diagnosis, BMI of 27 or higher, documented trial of metformin for 90 days, and HbA1c of 7.0% or higher. Ozempic is not covered for weight loss alone.

What is the difference between Wegovy and Ozempic? Both contain semaglutide. Wegovy is FDA-approved for weight loss and comes in doses up to 2.4 mg weekly. Ozempic is FDA-approved for diabetes and comes in doses up to 2 mg weekly. MassHealth covers Ozempic for diabetes but not Wegovy for obesity.

Can I get Wegovy covered if my BMI is over 40? No. MassHealth's obesity medication exclusion has no BMI threshold. Even patients with BMI over 40 and multiple obesity-related conditions have no coverage path for Wegovy without a diabetes diagnosis.

How much does Wegovy cost without insurance in Massachusetts? The retail price is $1,349.02 per month. Some pharmacies offer discount programs that reduce the cost to $900 to $1,000 per month, but this is still unaffordable for most MassHealth enrollees.

What is compounded semaglutide and is it the same as Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It costs $297 to $397 per month and does not require insurance or prior authorization. Clinical outcomes are comparable.

Does MassHealth cover Zepbound or Mounjaro? MassHealth covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization and step therapy requirements similar to Ozempic. Zepbound (tirzepatide for obesity) is not covered. The same pattern applies: diabetes indication covered, obesity indication excluded.

Can my doctor write a letter of medical necessity to get Wegovy covered? No. Medical necessity letters do not override formulary exclusions. Weight-loss medications are a statutorily excluded category under Massachusetts Medicaid law. Documentation of medical necessity is irrelevant when the drug category is not covered.

If I have diabetes and obesity, which medication should I ask for? Ask your provider to prescribe Ozempic and submit a prior authorization to MassHealth. If approved, you'll get coverage for up to 2 mg weekly, which provides meaningful weight loss even though it's less than the 2.4 mg Wegovy dose. If you want the higher dose, compounded semaglutide is the accessible alternative.

Does MassHealth cover bariatric surgery? Yes. MassHealth covers bariatric surgery (gastric bypass, sleeve gastrectomy) for patients with BMI ≥ 40, or BMI ≥ 35 with obesity-related comorbidities. Prior authorization is required, and you must complete a 6-month medically supervised weight-loss program before surgery.

Will MassHealth cover Wegovy in 2027? Possibly, but not certain. Two bills are under consideration in the Massachusetts legislature that would require MassHealth to cover obesity medications. If either passes, coverage would likely begin in fiscal year 2028 (July 2027). Until then, the obesity exclusion remains in effect.

Can I use a manufacturer coupon for Wegovy with MassHealth? No. Federal law prohibits using manufacturer coupons or copay assistance programs in combination with Medicaid. Novo Nordisk's Wegovy savings card explicitly excludes patients with government insurance.

How long does MassHealth prior authorization take for Ozempic? Standard prior authorization decisions are issued within 72 hours for urgent requests and 7 days for non-urgent requests. In practice, most diabetes medication prior authorizations are processed within 3 to 5 business days. Denials due to incomplete documentation add another 7 to 14 days if you need to resubmit.

Can I switch from MassHealth to a private plan to get Wegovy covered? Private insurance coverage for Wegovy varies by plan. Many employer-sponsored plans exclude obesity medications or require high copays ($100 to $500 per month). If you're eligible for subsidized Marketplace coverage, check the plan's formulary before switching. Losing MassHealth to pay more for private insurance that still doesn't cover Wegovy is not a good trade.

Does compounded semaglutide require a prescription? Yes. Compounded semaglutide is a prescription medication. You need a licensed provider to evaluate your eligibility, write a prescription, and monitor your progress. FormBlends connects patients with providers who specialize in GLP-1 therapy through telehealth consultations.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
4. Zhu D et al. GLP-1 Receptor Agonist Prior Authorization Patterns in Massachusetts Medicaid. Massachusetts Health Policy Commission Report. 2024.
5. MassHealth Pharmacy Program Annual Report. Massachusetts Executive Office of Health and Human Services. 2025.
6. MassHealth Drug List. Massachusetts Medicaid. January 2026 update.
7. Massachusetts General Law Chapter 118E: Medical Assistance for Low-Income Persons. 2026.
8. 130 CMR 406.413: MassHealth Pharmacy Services Excluded Drugs. 2026.
9. Hendricks EJ et al. Comparative Effectiveness of Compounded vs Brand Semaglutide for Weight Management. Obesity Science & Practice. 2024.
10. Massachusetts Department of Public Health. Obesity Prevalence Data by Insurance Status. 2025.
11. Massachusetts Executive Office of Health and Human Services. Fiscal Impact Analysis: Anti-Obesity Medication Coverage. 2023.
12. MassHealth Board of Hearings Annual Report. 2025.
13. House Bill 2147: An Act Relative to Coverage of Anti-Obesity Medications. Massachusetts Legislature. 2025.
14. Senate Bill 891: An Act to Improve Access to Obesity Treatment. Massachusetts Legislature. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. MassHealth is a registered service mark of the Commonwealth of Massachusetts. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.